Akebia Therapeutics (AKBA) Competitors $3.25 -0.04 (-1.22%) Closing price 08/15/2025 04:00 PM EasternExtended Trading$3.22 -0.03 (-0.92%) As of 08/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock AKBA vs. AAPG, PTCT, MLTX, PTGX, MIRM, MTSR, INDV, SRRK, APLS, and MORShould you be buying Akebia Therapeutics stock or one of its competitors? The main competitors of Akebia Therapeutics include Ascentage Pharma Group International (AAPG), PTC Therapeutics (PTCT), MoonLake Immunotherapeutics (MLTX), Protagonist Therapeutics (PTGX), Mirum Pharmaceuticals (MIRM), Metsera (MTSR), Indivior (INDV), Scholar Rock (SRRK), Apellis Pharmaceuticals (APLS), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Akebia Therapeutics vs. Its Competitors Ascentage Pharma Group International PTC Therapeutics MoonLake Immunotherapeutics Protagonist Therapeutics Mirum Pharmaceuticals Metsera Indivior Scholar Rock Apellis Pharmaceuticals MorphoSys Akebia Therapeutics (NASDAQ:AKBA) and Ascentage Pharma Group International (NASDAQ:AAPG) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, earnings, risk, media sentiment, dividends and profitability. Do analysts prefer AKBA or AAPG? Akebia Therapeutics currently has a consensus target price of $6.75, suggesting a potential upside of 107.69%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Akebia Therapeutics is more favorable than Ascentage Pharma Group International.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Akebia Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Ascentage Pharma Group International 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer AKBA or AAPG? In the previous week, Akebia Therapeutics had 2 more articles in the media than Ascentage Pharma Group International. MarketBeat recorded 7 mentions for Akebia Therapeutics and 5 mentions for Ascentage Pharma Group International. Akebia Therapeutics' average media sentiment score of 0.73 beat Ascentage Pharma Group International's score of 0.68 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascentage Pharma Group International 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, AKBA or AAPG? Ascentage Pharma Group International has lower revenue, but higher earnings than Akebia Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAkebia Therapeutics$160.18M5.38-$69.41M-$0.17-19.12Ascentage Pharma Group International$134.35M31.13-$55.54MN/AN/A Do insiders and institutionals have more ownership in AKBA or AAPG? 33.9% of Akebia Therapeutics shares are owned by institutional investors. 3.0% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Is AKBA or AAPG more profitable? Ascentage Pharma Group International has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -17.91%. Company Net Margins Return on Equity Return on Assets Akebia Therapeutics-17.91% N/A -13.47% Ascentage Pharma Group International N/A N/A N/A SummaryAkebia Therapeutics beats Ascentage Pharma Group International on 9 of the 13 factors compared between the two stocks. Get Akebia Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AKBA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AKBA vs. The Competition Export to ExcelMetricAkebia TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$861.72M$2.55B$5.74B$9.80BDividend YieldN/A1.76%3.91%4.13%P/E Ratio-19.1222.4731.1125.06Price / Sales5.38548.91434.0899.81Price / CashN/A170.4436.7858.67Price / Book29.555.079.086.18Net Income-$69.41M$31.61M$3.26B$265.11M7 Day Performance-4.97%25.12%7.38%4.22%1 Month Performance-16.24%2.78%4.21%0.77%1 Year Performance125.69%10.98%30.29%24.69% Akebia Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AKBAAkebia Therapeutics4.0764 of 5 stars$3.25-1.2%$6.75+107.7%+125.7%$861.72M$160.18M-19.12430AAPGAscentage Pharma Group InternationalN/A$40.04-4.6%N/AN/A$3.49B$980.65M0.00600News CoverageGap UpPTCTPTC Therapeutics4.4561 of 5 stars$43.30-4.6%$70.15+62.0%+46.1%$3.44B$806.78M6.211,410News CoverageMLTXMoonLake Immunotherapeutics2.5672 of 5 stars$53.38+1.9%$74.43+39.4%+12.9%$3.42BN/A-19.202Analyst RevisionPTGXProtagonist Therapeutics2.0687 of 5 stars$53.75+5.2%$67.20+25.0%+35.4%$3.34B$434.43M76.79120Positive NewsMIRMMirum Pharmaceuticals3.4457 of 5 stars$65.87+9.8%$74.13+12.5%+66.9%$3.31B$336.89M-54.44140News CoverageAnalyst UpgradeInsider TradeHigh Trading VolumeMTSRMetseraN/A$30.14-0.9%$55.00+82.5%N/A$3.17BN/A0.0081INDVIndivior2.404 of 5 stars$22.29+1.3%$19.60-12.1%+85.6%$3.07B$1.17B35.951,051SRRKScholar Rock4.497 of 5 stars$31.46-1.5%$45.14+43.5%+237.0%$3.02B$33.19M-10.81140APLSApellis Pharmaceuticals4.1008 of 5 stars$23.85-2.1%$34.12+43.1%-25.5%$3.01B$781.37M-13.10770Short Interest ↑MORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive News Related Companies and Tools Related Companies AAPG Alternatives PTCT Alternatives MLTX Alternatives PTGX Alternatives MIRM Alternatives MTSR Alternatives INDV Alternatives SRRK Alternatives APLS Alternatives MOR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AKBA) was last updated on 8/17/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredNew Federal Land Rush About to Start?A $100 Trillion Wealth Shift Is Already Underway Lithium. Oil. Gold. Trillions in U.S. resources are being ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akebia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akebia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access